Amarin Corp Plcuk (AMRN) Other Accumulated Expenses (2010 - 2025)
Amarin Corp Plc\Uk (AMRN) posted quarterly Other Accumulated Expenses of $18.3 million for Q4 2025, up 4.52% year-over-year from $17.5 million in Q4 2024, and up 4.52% quarter-over-quarter from $17.5 million in Q4 2024.
Amarin Corp Plcuk (AMRN) Other Accumulated Expenses (2010 - 2025) Analysis & Trends
Amarin Corp Plc\Uk (AMRN) has reported Other Accumulated Expenses for 16 consecutive years, with $18.3 million the latest figure, recorded in Q4 2025.
- In Q4 2025, Other Accumulated Expenses rose 4.52% year-over-year to $18.3 million; the TTM figure through Dec 2025 stood at $18.3 million (up 4.52% YoY), while the FY2025 annual figure was $18.3 million, up 4.52% from the prior year.
- Other Accumulated Expenses improved to $18.3 million in Q4 2025 per AMRN's latest filing, from $17.5 million in the prior quarter.
- Across five years, Other Accumulated Expenses topped out at $45.6 million in Q4 2021 and bottomed at $17.5 million in Q4 2024.
- Historically, Other Accumulated Expenses has averaged $28.0 million across 5 years, with a median of $23.0 million in 2023.
- Annual changes were most pronounced in 2021 — Other Accumulated Expenses surged 58.42% — and 2023, when it sank 35.41%.
- Amarin Corp Plc\Uk's Other Accumulated Expenses stood at $45.6 million in 2021, then retreated by 21.84% to $35.6 million in 2022, then tumbled by 35.41% to $23.0 million in 2023, then slipped by 23.79% to $17.5 million in 2024, then climbed by 4.52% to $18.3 million in 2025.
- Business Quant data shows AMRN's Other Accumulated Expenses at $18.3 million in Q4 2025, $17.5 million in Q4 2024, and $23.0 million in Q4 2023.
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) |
|---|---|---|---|---|
| 1 | Johnson & Johnson | 652.20 Bn | 631.44 Bn | 17.26 Bn |
| 2 | AbbVie | 469.51 Bn | 462.94 Bn | 12.70 Bn |
| 3 | Merck | 376.81 Bn | 369.67 Bn | 12.21 Bn |
| 4 | Novartis Ag | 303.04 Bn | 295.35 Bn | 11.24 Bn |
| 5 | Astrazeneca | 257.61 Bn | 252.71 Bn | 12.86 Bn |
| 6 | Amgen | 237.37 Bn | 223.38 Bn | 7.24 Bn |
| 7 | Gilead Sciences | 181.73 Bn | 178.55 Bn | 6.22 Bn |
| 8 | Pfizer | 159.66 Bn | 147.96 Bn | 10.94 Bn |
| 9 | Gsk | 106.24 Bn | 102.07 Bn | 8.24 Bn |
| 10 | Amarin Corp Plcuk | 5.86 Bn | 5.54 Bn | 14.99 Mn |
Historic Data
Download Data| Date | Value |
|---|---|
| Dec 31, 2025 | 18.34 Mn |
| Dec 31, 2024 | 17.55 Mn |
| Dec 31, 2023 | 23.02 Mn |
| Dec 31, 2022 | 35.64 Mn |
| Dec 31, 2021 | 45.60 Mn |
| Dec 31, 2020 | 28.79 Mn |
| Dec 31, 2019 | 16.59 Mn |
| Dec 31, 2018 | 7.71 Mn |
| Dec 31, 2017 | 5.16 Mn |
| Dec 31, 2016 | 5.80 Mn |
| Dec 31, 2015 | 4.28 Mn |
| Dec 31, 2014 | 2.25 Mn |
| Dec 31, 2013 | 3.34 Mn |
| Dec 31, 2012 | 3.15 Mn |
| Dec 31, 2011 | 1.78 Mn |
| Dec 31, 2010 | 572,000.00 |